Table 3 Risk of MACE and composite CV events in patients on GnRH antagonists compared with patients on GnRH agonists by pre-existing cardiovascular disease.

From: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan

 

MACE

Composite CV eventsa

 

No. of events

aHRb

(95% CI)

P value

No. of events

aHRc

(95% CI)

P value

All

  GnRH antagonist (n = 499)

136

0.97

(0.81–1.17)

0.7665

24

0.34

(0.21–0.55)

<0.0001

  GnRH agonist (n = 15,127)

5105

–

  

2001

–

  

Pre-existing CVDd

  GnRH antagonist (n = 167)

39

0.67

(0.46–0.96)

0.0299

5

0.16

(0.05–0.50)

0.0017

  GnRH agonist (n = 3348)

1046

–

  

462

–

  

No pre-existing CVD

  GnRH antagonist (n = 332)

97

1.23

(0.91–1.40)

0.2901

19

0.44

(0.26–0.74)

0.0019

  GnRH agonist (n = 11,779)

4059

–

  

1539

–

  
  1. aHR adjusted hazard ratio, CV cardiovascular, CVD, cardiovascular disease(s), GnRH gonadotropin-releasing hormone, MACE major adverse cardiovascular event (ischemic heart disease, stroke, congestive heart failure or all cause deaths), occurring ≥90 days after ADT initiation, whichever came first.
  2. aComposite CV events: ischemic heart disease, stroke, congestive heart failure or CV deaths occurring ≥90 days after ADT initiation, whichever came first.
  3. bAdjusted hazard ratios were estimated using cox model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
  4. cAdjusted hazard ratios were estimated using the Fine and Gray competing risk model adjusted for age, cancer stage, receiving chemotherapy, radiation therapy, antiandrogen, abiraterone, and enzalutamide.
  5. dPre-existing CVD: receiving cardiac therapy, diagnosis of ischemic heart diseases, stroke, or congestive heart failure 1 year before androgen deprivation therapy initiation.
Back to article page